New Horizon's eVTOL keeps advancing. So does the share count.

New Horizon Aircraft reported fiscal fourth-quarter results on July 16 with a headline that reads well in isolation: about $78.3 million in cash, which the company says is more than 24 months of liquidity to complete the full-scale Cavorite X7 demonstrator and support certification and manufacturing work. It also said the first full-scale X7 prototype is on track to begin initial testing in the first quarter of calendar 2027. On July 9 it named BETA Technologies to supply the advanced fly-by-wire flight control computers for the aircraft, a credible engineering choice.

Now read the balance sheet the other way. That strengthened cash position came from a $25 million registered direct offering of 9,960,160 Class A shares. The pattern that defines this stock is not the engineering, which advances milestone by milestone, but the financing, which arrives raise by raise. Each technical step forward is funded by issuing more equity, and the aircraft is still pre-full-scale-testing.

The dilution schedule is the thesis

eVTOL development is a long, cash-hungry road, and New Horizon is pre-revenue with its most expensive and highest-risk work, full-scale testing and certification, still ahead. Companies in that position return to the market repeatedly, and the $25 million raise is the latest installment. A 24-month runway sounds comfortable until you remember that full-scale demonstration, flight testing, and certification each tend to cost more and take longer than planned, which means more raises are the base case, not the exception.

The other side

The bull would say the technology is progressing, the BETA selection de-risks a critical subsystem, and the balance sheet is in better shape than many eVTOL peers. All true. But better-funded than peers is a low bar in a sector that has been a serial diluter across the board, and none of it changes that the value-inflection event, a flying full-scale aircraft, is still in front of the company and will be expensive to reach.

• Dilution is the pattern. The strengthened balance sheet came from a $25M raise of nearly 10 million shares; more raises are the base case.
• Pre-revenue, pre-full-scale-testing. The most expensive and riskiest work is still ahead, with first full-scale testing not until Q1 2027.
• Long certification road. Flight testing and certification routinely cost more and take longer than planned.

What to watch

The timing of first full-scale Cavorite X7 testing in early 2027 and, just as important, the next financing. The engineering can keep hitting marks and the equity can still grind lower if the dilution outpaces the progress. That is the tension the stock has to resolve.